CorMedix (CRMD) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics (IRD) has outperformed CorMedix (CRMD) over the past year, gaining 108.9% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -8.3% for IRD. CorMedix is the larger company by market cap ($419.2 million vs $385.7 million), about 1.1 times the size.
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -349.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | IRD |
|---|---|---|
| Share price | $5.27 | $3.99 |
| Market cap | $419.16M | $385.65M |
| 1-day change | +3.74% | -2.21% |
| YTD return | -54.69% | +98.51% |
| 1-year return | -45.56% | +108.90% |
| 5-year return | +3.94% | -8.28% |
| P/E ratio (TTM) | 8.23 | — |
| Forward P/E | 15.06 | — |
| EPS (TTM) | $0.64 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $14.20M |
| Revenue growth (YoY) | +617.03% | +29.15% |
| Net income (latest FY) | $163.06M | $-49.59M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -271.90% |
| Net margin | 52.31% | -349.33% |
| 52-week high | $13.02 | $7.07 |
| 52-week low | $4.47 | $1.88 |
| Distance from 52-week high | -59.52% | -43.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +161.86% | +249.37% |
| Average volume | 1.44M | 2.56M |
| Shares outstanding | 79.54M | 96.65M |
| Employees | 191 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed CRMD by 154.5 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -349.3 cents for Opus Genetics.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +29.15%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
CRMD vs IRD FAQ
Which is bigger, CorMedix or Opus Genetics?
CorMedix (CRMD) is larger, with a market capitalization of $419.16M compared with $385.65M for Opus Genetics (IRD).
Which stock has performed better over the past year, CRMD or IRD?
IRD returned +108.90% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.